Synaptogenix (NASDAQ:TAOX) Shares Down 3.4% – Here’s What Happened

Synaptogenix, Inc. (NASDAQ:TAOX)’s stock price traded down 3.4% during mid-day trading on Tuesday . The company traded as low as $3.56 and last traded at $3.72. 68,949 shares were traded during mid-day trading, a decline of 52% from the average session volume of 142,797 shares. The stock had previously closed at $3.85.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Wall Street Zen raised Synaptogenix from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Synaptogenix in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Synaptogenix has a consensus rating of “Sell”.

Synaptogenix Stock Down 3.4%

The firm’s 50-day moving average price is $4.99 and its 200-day moving average price is $5.03. The company has a market cap of $27.79 million, a P/E ratio of -0.28 and a beta of 1.41.

Synaptogenix (NASDAQ:TAOX) last released its quarterly earnings data on Wednesday, May 13th. The company reported $0.43 earnings per share for the quarter. The business had revenue of $5.96 million during the quarter.

About Synaptogenix

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.